FeesSafety
Pluang+

FDA approves Livsayis, first siRNA therapy for generalized myasthenia gravis with quarterly dosing

Market News
19 Nov 2026, 01:03 WIB
GlobeNewsWire
View Source
Bullish
FDA approves Livsayis, first siRNA therapy for generalized myasthenia gravis with quarterly dosing

The FDA has approved Livsayis (cemdisiran), the first siRNA therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-AChR antibody-positive. Livsayis offers a novel treatment by targeting complement component C5, reducing disease activity with a convenient subcutaneous injection four times a year. Approval was based on Phase 3 NIMBLE trial results showing significant and sustained improvements in muscle function and daily living activities compared to placebo. Regeneron plans regulatory submissions in the EU and Japan next, aiming to expand access globally.

Regeneron Pharmaceuticals Inc (REGN) has a market cap of $99.08 billion and a dividend yield of 0.39% as of Nov 19, 2026 06:11 WIB. On Pluang, REGN shares are priced at USD 945.53, down 1.28% for the day, with a typical hold time of 109 days. The stock shows a high sell order activity at 90%, reflecting cautious investor sentiment despite the FDA approval news.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App